home / stock / tgtx / tgtx quote
Last: | $13.78 |
---|---|
Change Percent: | 0.86% |
Open: | $13.87 |
Close: | $13.78 |
High: | $14.015 |
Low: | $13.26 |
Volume: | 3,665,833 |
Last Trade Date Time: | 04/19/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$13.78 | $13.87 | $13.78 | $14.015 | $13.26 | 3,665,833 | 04-19-2024 |
$13.99 | $13.99 | $13.99 | $14.63 | $13.85 | 3,483,820 | 04-18-2024 |
$13.82 | $14.06 | $13.82 | $14.14 | $13.55 | 3,076,512 | 04-17-2024 |
$14 | $13.98 | $14 | $14.17 | $13.7648 | 1,614,576 | 04-16-2024 |
$14.07 | $14.15 | $14.07 | $14.575 | $13.945 | 2,269,304 | 04-15-2024 |
$14.16 | $14.76 | $14.16 | $14.87 | $13.91 | 3,880,506 | 04-12-2024 |
$14.76 | $14.81 | $14.76 | $14.99 | $14.585 | 2,242,319 | 04-11-2024 |
$14.71 | $14.56 | $14.71 | $15.065 | $14.44 | 2,985,390 | 04-10-2024 |
$15.1 | $15.16 | $15.1 | $15.37 | $14.976 | 1,943,180 | 04-09-2024 |
$14.97 | $14.62 | $14.97 | $15.0266 | $14.31 | 2,003,394 | 04-08-2024 |
$14.52 | $14.36 | $14.52 | $14.645 | $14.19 | 2,299,596 | 04-05-2024 |
$14.46 | $14.65 | $14.46 | $14.875 | $14.38 | 2,635,213 | 04-04-2024 |
$14.47 | $14.39 | $14.47 | $14.5881 | $14.04 | 2,289,538 | 04-03-2024 |
$14.44 | $14.43 | $14.44 | $14.59 | $14.13 | 2,768,395 | 04-02-2024 |
$14.77 | $15.13 | $14.77 | $15.18 | $14.65 | 2,219,609 | 04-01-2024 |
$15.21 | $15.56 | $15.21 | $15.6 | $15.145 | 2,328,111 | 03-29-2024 |
$15.21 | $15.56 | $15.21 | $15.6 | $15.145 | 2,328,111 | 03-28-2024 |
$15.57 | $15.55 | $15.57 | $15.615 | $15.055 | 1,454,844 | 03-27-2024 |
$15.44 | $15.83 | $15.44 | $15.99 | $15.24 | 2,651,466 | 03-26-2024 |
$15.69 | $15.46 | $15.69 | $15.82 | $15.4 | 1,770,918 | 03-25-2024 |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ:TGTX), announced that it has been awarded a national contract with th...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at t...
NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced that it has been awarded a national contract with the Department of Veterans Affairs (VA) for BRIUMVI® (ublituximab-xiiy) to be the preferred agent listed on the VA National Formulary for Anti-CD20 A...